Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia
| Autor: | Anne C. Goldberg, Harold E. Bays, Carolyn M. Setze, Susan M. Buttler, Darryl J. Sleep, Maureen T. Kelly, Christie M. Ballantyne, James C. Stolzenbach |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty Combination therapy Atorvastatin Gastroenterology chemistry.chemical_compound Pharmacotherapy Double-Blind Method Fenofibrate Internal medicine medicine Humans Pyrroles Triglycerides Aged Dyslipidemias business.industry Cholesterol Anticholesteremic Agents Cholesterol HDL nutritional and metabolic diseases Cholesterol LDL Middle Aged medicine.disease Treatment Outcome Endocrinology chemistry Heptanoic Acids Toxicity Cardiology Drug Therapy Combination Female lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Dyslipidemia Lipoprotein medicine.drug |
| Zdroj: | The American Journal of Cardiology. 103:515-522 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2008.10.025 |
| Popis: | In patients with mixed dyslipidemia characterized by increased triglycerides (TG), decreased high-density lipoprotein (HDL) cholesterol, and increased low-density lipoprotein (LDL) cholesterol, monotherapy with lipid-altering drugs often fails to achieve all lipid targets. This multicenter, double-blind, active-controlled study evaluated ABT-335 (fenofibric acid) in combination with 2 doses of atorvastatin in patients with mixed dyslipidemia. A total of 613 patients with LDL cholesterol > or =130 mg/dl, TG > or =150 mg/dl, and HDL cholesterol |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect